Throughout the MSD Innovation Factory, MSD launched 7 health-related challenges to award the three most outstanding solutions. Blendarsys, Symptoma and Grupo Pulso are the winners out of 100 proposals. The companies will receive up to $20,000 each to co-create and roll-out their solution with MSD support.

eHealthNews.eu is proud to announce the top 20 most popular eHealth News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular success!

AI health companion, Ada Health intensifies collaboration with German Accelerator Life Sciences (GALS) as it expands to the US. Following the successful closing of a $47M funding round, Ada will accelerate operational and partnership developments in a rapidly growing US market. The London and Berlin-based health technology company has developed a health companion and telemedicine app as well as a decision support tool for medical professionals, which launched in late 2016.

The Personal Connected Health Alliance (PCHAlliance) today released the latest version of the Continua Design Guidelines (CDGs) to enable the secure, private, reliable and accurate sharing of patient generated health data (PGHD) with healthcare providers, built-on HL7 FHIR (Fast Healthcare Interoperability Resources) specifications. The Design Guidelines now support the integration of personal health data from

Rockstart Digital Health Accelerator provides an unparalleled access to the healthcare ecosystem, capital, coaching and investors for entrepreneurs who are looking to change the way things are done in healthcare. It will help you better understand product design, market fit and business models by enabling you to directly work with patients, professionals and other stakeholders.

Vertical is not your typical startup accelerator, it does not cover startups pitch training, vision/mission or product-market-fit. VERTICAL expects entrepreneurs to have the fundamentals of their ventures in place. Vertical team combines the tenacity of start-up fervour with the experienced corporate world, the accelerator collaborates to create industry-first developments and pave the way forward.

Boehringer Ingelheim has announced the launch of opnME.com, a new platform offering free and open access to selected pre-clinical molecules for non-clinical investigation to scientists worldwide. Through opnME.com, molecules for some of the most relevant targets in biomedical research are shared, thereby creating possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients.